Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Advanced or metastatic breast cancer (BC) presents significant treatment challenges and a poorer prognosis compared to early-stage disease.
• Targeted therapies, particularly those affecting the cell-cycle machinery, demonstrate potential in preclinical BC models.
• The cyclin D/CDK/retinoblastoma pathway is crucial in BC, and its inhibition offers a therapeutic strategy.

Purpose of the Study:

• To review the preclinical and clinical data for abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
• To examine the therapeutic indications, ongoing research, and future directions for abemaciclib in breast cancer treatment.
• To highlight the role of CDK4/6 inhibitors in combination with endocrine therapy for hormone receptor-positive BC.

Main Methods:

• Review of preclinical studies investigating the mechanism of action of CDK4/6 inhibitors.
• Analysis of clinical trial data, including MONARCH 1 and 2, evaluating abemaciclib efficacy and safety.
• Synthesis of current therapeutic guidelines and ongoing research for abemaciclib in breast cancer.

Main Results:

• CDK4/6 inhibitors, including abemaciclib, induce cell-cycle arrest and tumor shrinkage by targeting the cyclin D/CDK/retinoblastoma pathway.
• Combination therapy with CDK4/6 inhibitors and endocrine therapy is superior to endocrine therapy alone in hormone receptor-positive BC.
• Abemaciclib has received FDA approval based on positive trial outcomes, demonstrating clinical activity.

Conclusions:

• Abemaciclib represents a significant advancement in the treatment of advanced or metastatic hormone receptor-positive breast cancer.
• Further clinical trials are necessary to address remaining questions and optimize the use of abemaciclib.
• The combination of CDK4/6 inhibitors with endocrine therapy is a validated and effective strategy for managing advanced BC.